HRP20201165T1 - Uporaba inhibitora ccr3 - Google Patents

Uporaba inhibitora ccr3 Download PDF

Info

Publication number
HRP20201165T1
HRP20201165T1 HRP20201165TT HRP20201165T HRP20201165T1 HR P20201165 T1 HRP20201165 T1 HR P20201165T1 HR P20201165T T HRP20201165T T HR P20201165TT HR P20201165 T HRP20201165 T HR P20201165T HR P20201165 T1 HRP20201165 T1 HR P20201165T1
Authority
HR
Croatia
Prior art keywords
compound
chloride
eosinophilic
use according
methyl
Prior art date
Application number
HRP20201165TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Alkahest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201165(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest, Inc. filed Critical Alkahest, Inc.
Publication of HRP20201165T1 publication Critical patent/HRP20201165T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
HRP20201165TT 2012-04-03 2013-04-02 Uporaba inhibitora ccr3 HRP20201165T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors
EP13713199.1A EP2833884B1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
HRP20201165T1 true HRP20201165T1 (hr) 2020-12-11

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201165TT HRP20201165T1 (hr) 2012-04-03 2013-04-02 Uporaba inhibitora ccr3

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP4389217A3 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20210063481A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
NZ757769A (en) * 2017-04-05 2025-10-31 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2020536929A (ja) * 2017-10-13 2020-12-17 アルカヘスト,インコーポレイテッド Ccr3阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
AU2019271122A1 (en) 2018-05-15 2020-11-12 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
CA3111433A1 (en) * 2018-09-26 2020-04-02 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2023529719A (ja) * 2020-06-11 2023-07-11 アルカヘスト,インコーポレイテッド Ccr3阻害剤を使用した網膜関連疾患の転帰改善方法
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL151499A0 (en) * 2000-03-03 2003-04-10 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
CY1123222T1 (el) 2021-10-29
WO2013149986A1 (en) 2013-10-10
LT2833884T (lt) 2020-09-10
PH12014502239A1 (en) 2014-12-15
KR20200044988A (ko) 2020-04-29
US20200375971A1 (en) 2020-12-03
BR112014023795A2 (enExample) 2017-06-20
US20130261153A1 (en) 2013-10-03
KR20250133980A (ko) 2025-09-09
KR20210063481A (ko) 2021-06-01
HUE051648T2 (hu) 2021-03-29
US20170319567A1 (en) 2017-11-09
US20160081998A1 (en) 2016-03-24
JP2015512432A (ja) 2015-04-27
EA201401083A1 (ru) 2015-03-31
IN2014DN06989A (enExample) 2015-04-10
EP3763369B1 (en) 2024-02-28
AU2013245027B2 (en) 2017-10-12
US20150099783A1 (en) 2015-04-09
SI2833884T1 (sl) 2020-10-30
DK2833884T3 (da) 2020-08-10
NZ628882A (en) 2016-05-27
KR20220132012A (ko) 2022-09-29
MX2014011786A (es) 2014-12-05
CL2014002523A1 (es) 2015-01-23
PT2833884T (pt) 2020-08-26
RS60665B1 (sr) 2020-09-30
CN104220073A (zh) 2014-12-17
AU2013245027A1 (en) 2014-09-11
ES2987267T3 (es) 2024-11-14
CN110384699A (zh) 2019-10-29
KR20140144200A (ko) 2014-12-18
EP2833884A1 (en) 2015-02-11
EP4389217A2 (en) 2024-06-26
EP4389217A3 (en) 2024-08-28
CA2869269C (en) 2020-06-30
PL2833884T3 (pl) 2020-11-02
ES2811554T3 (es) 2021-03-12
BR112014023795B1 (pt) 2021-09-08
EA032263B1 (ru) 2019-05-31
CA2869269A1 (en) 2013-10-10
SMT202000499T1 (it) 2020-11-10
ZA201406082B (en) 2019-01-30
EP3763369A1 (en) 2021-01-13
JP2018080183A (ja) 2018-05-24
BR112014023795A8 (pt) 2017-10-10
IL234262A (en) 2017-10-31
EP2833884B1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
HRP20201165T1 (hr) Uporaba inhibitora ccr3
BR112015022861A2 (pt) inibidores de bromodomínio
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BRPI1009637A2 (pt) composto, composição e uso de um composto
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
NZ715747A (en) Syk inhibitors
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
GEP20146125B (en) Aminopyrimidines as syk inhibitors
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators